<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00720018</url>
  </required_header>
  <id_info>
    <org_study_id>PROT-15-NP101-006</org_study_id>
    <nct_id>NCT00720018</nct_id>
  </id_info>
  <brief_title>Phase I Open Label Single-Dose Study to Compare the Pharmacokinetics of NP101 Healthy Volunteers</brief_title>
  <acronym>NP101-006</acronym>
  <official_title>A Phase I, Single Center, Open Label, Single-Dose, Five-Period Study to Compare the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NuPathe Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to compare the pharmacokinetics (PK) profiles among five NP101
      patches in healthy volunteers.

      The secondary objective is to evaluate the safety of NP101 in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective was to compare the pharmacokinetics (PK) profiles among five NP101 patches in healthy volunteers.</measure>
    <time_frame>Blood samples were collected at time points: pre-dose (within 15 minutes prior to dosing) and at 0.25, 0.50, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 16 hrs post-dose.</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Migraine Disorders</condition>
  <arm_group>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NP101 Patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NP101 Patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NP101 Patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NP101 Patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NP101 Patch</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NP101 Sumatriptan Iontophoretic Transdermal Patch</intervention_name>
    <description>NP101 transdermal patch delivering sumatriptan for 4 hours.</description>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_label>Period 2</arm_group_label>
    <arm_group_label>Period 3</arm_group_label>
    <arm_group_label>Period 4</arm_group_label>
    <arm_group_label>Period 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Caucasian men or women aged 18 to 45.

          -  Subjects have BMI of 18 to 30 kg/m2 inclusive.

          -  Subject judged to be in good health, based upon the results of a medical history,
             physical examination, vital signs, ECG and laboratory profile. Subjects will not have
             any clinically significant abnormal findings in order to qualify for enrollment.

          -  Subject must have a negative drug screen at screening and on Day -1 for all treatment.

          -  Subjects must be nonsmokers, defined as having not used any tobacco products in the 6
             months before screening.

          -  The subjects will have received no other medication except birth control, for two
             weeks prior to study entry.

          -  Subjects must have not consumed alcoholic beverages, poppy seeds, grapefruit, and/or
             grapefruit juice within 72 hours prior to admission.

          -  Female of childbearing potential must have a negative pregnancy test at screening and
             on Day -1 for all treatment.

          -  In the investigator's opinion, the subject must be likely to complete the study.

          -  Subjects must be able to communicate effectively and be capable of reading and
             understanding English and voluntarily sign an IRB approved IC agreement.

        Exclusion Criteria:

          -  Subject has a history of allergy or hypersensitivity to any component of the study
             patch used in this study.

          -  Subject has any generalized skin irritation or disease including eczema, psoriasis,
             melanoma, contact dermatitis or acne.

          -  Subject has a tattoo that might interfere with skin irritation examination.

          -  Subject has a history of epilepsy or conditions associated with a lowered seizure
             threshold.

          -  Subject has a history of basilar or hemiplegic migraines.

          -  Subject has suspected or confirmed cardiovascular disease that contraindicates
             participation.

          -  Subject has Raynaud's disease.

          -  Subject has a history (within 1 year) or current evidence of drug or alcohol abuse or
             dependence.

          -  Subject with a history of malignancy within the past 5 years.

          -  Subject has clinically significant abnormal laboratory parameters, vital signs or ECG
             parameters.

          -  Subject has SGOT/AST, SGPT/ALT, alkaline phosphatase or total bilirubin â‰¥ 1.5 times
             the upper limit of normal.

          -  Subject with a hemoglobin (Hgb) level of less than 7.5 mmol/L.

          -  Subject is hepatitis B, hepatitis C or HIV positive.

          -  Subject has taken an MAO inhibitor, preparations containing St. John's Wort, SSRI,
             SNRI, TCA, triptan or ergot medication, within one month prior to screening.

          -  Subject is unwilling to discontinue the use of phosphodiesterase type 5 inhibitor,
             from screening through the End of Study.

          -  Subject who has been administered an injectable drug, except for local anesthetic or
             birth control, within 30 days prior to the initial study drug administration.

          -  Donation of blood or blood products within 8 weeks prior to study entry.

          -  Receipt of an investigational drug or participation in any clinical study within 90
             days prior to study.

          -  Subject who requires any medication on a regular basis, with the exception of
             steroidal contraceptives.

          -  Concurrent use of Rx or OTC medications or natural medicine (herbal) products, with
             the exception of steroidal contraceptives.

          -  Female subject who is pregnant, planning a pregnancy during the study, breast feeding;
             or if of childbearing potential, not using or unwilling to use an effective form of
             contraception during the study and for a period of 30 days following dosing.

          -  Subject who is considered to be an unsuitable candidate for receiving sumatriptan, or
             as being unsuitable for any other reason.

          -  Subject is electrically sensitive (e.g., prior iontophoresis with adverse outcome
             related to the current delivered by the device) or who have an implantable electronic
             device (e.g., pacemaker).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shannon M Canas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prism Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prism Research</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2008</study_first_submitted>
  <study_first_submitted_qc>July 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2008</study_first_posted>
  <last_update_submitted>February 2, 2016</last_update_submitted>
  <last_update_submitted_qc>February 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sumatriptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

